Status: Recruiting
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.
Participants needed: 550
Trial details
Phase: Phase 3Age: 55+Biological sex: AllType: InterventionalSponsor: Eli Lilly and CompanyUpdated: Jun 26, 2026Locations: 58
Eligibility criteria
Have completed study AACM Addendum 7. [+3]
Current serious or unstable illnesses that, in the investigator's opinion, could... [+5]